TGF-β Signaling Pathway Assay (CAT#: STEM-MB-0347-WXH)

Generally speaking, signal transduction starts with ligand-induced oligomerization of serine/threonine receptor kinases and phosphorylation of cytoplasmic signal transduction molecules, which are in the TGF-β/activin pathway It is Smad2 and Smad3, and in the bone morphogenetic protein (BMP) pathway it is Smad1/5/9. The carboxyl terminus of Smads is phosphorylated by the activated receptor, which causes it to bind to the common signal transduction factor Smad4 and is transported into the nucleus. Activated Smads can regulate various biological effects by binding to transcription factors, leading to specific transcriptional regulation of cell states. Inhibitory Smads, such as Smad6 and Smad7, can antagonize the activation of R-Smads. The expression of inhibitory Smads (I-Smads) 6 and 7 is induced by activin/TGF-β and BMP signal transduction together, as part of a negative feedback loop.

To study the effect of each virus on TGF-β signaling pathway
To study the regulation mechanism of TGF-β signal pathway in disease
To study the effects of drugs or therapies on TGF-β signaling pathways

• Luminex Multiplex Assay
• Enzyme-linked immunosorbent assay (ELISA)
• Flow cytometry (FACS analysis) technology

Detectable targets: RhoA, Rac, Cdc42, Shc, GRB2, SOS, Ras, Smad1, Smad5, Smad9, SARA, Smad2, Smad3, Smad7, Smad4, Smad6, mDia, ROCK, PAK, Par6, PKC, MLC, LIMK, C-Abl, Cofilin, PI3k, Akt, mTOR, TAK1, S6k, PP2A, JNK, Smurf2, p70, p38, NF-kB, Erk1, Erk2, LIMK, CBP, TMEPAI